Beaufort Securities restated their speculative buy rating on shares of N4 Pharma PLC (LON:N4P) in a research report report published on Thursday morning.

TRADEMARK VIOLATION NOTICE: “N4 Pharma PLC (LON:N4P) Receives “Speculative Buy” Rating from Beaufort Securities” was first posted by Watch List News and is owned by of Watch List News. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright law. The original version of this story can be viewed at https://www.watchlistnews.com/n4-pharma-plc-lonn4p-receives-speculative-buy-rating-from-beaufort-securities/1463159.html.

N4 Pharma PLC Company Profile

N4 Pharma Plc, formerly Onzima Ventures plc, is a United Kingdom-based specialist pharmaceutical company. The Company is engaged in reformulating existing drugs and vaccines to improve their performance. It operates in two divisions: generic and vaccines. Its generics division includes Sildenafil, Sartans, Aprepitant and Single dose Hepatitis B.

Receive News & Ratings for N4 Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for N4 Pharma PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.